UBS AM’s Cartesian Therapeutics RNAC Stock Holding History

UBS AM’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$47.2K	Hold	4,533	–	–	﹤0.01%	2941
2026 Q1	$27.9K	Buy	4,533 +4,017	+778%	+$28.6K	﹤0.01%	3079
2025 Q4	$3.72K	Buy	+516	New	+$4.17K	﹤0.01%	3030

Other funds holding RNAC

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS AM's RNAC Position: Q2 2026 in Review

UBS AM held its Cartesian Therapeutics (RNAC) position steady in Q2 2026 at 4,533 shares worth $47.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2941.

UBS AM first reported a position in RNAC in Q4 2025 and has held it in 3 quarters since. 95 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

UBS AM held 4,533 shares of Cartesian Therapeutics worth $47.2K as of Q2 2026.
UBS AM left its Cartesian Therapeutics share count unchanged in Q2 2026.
Cartesian Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #2941 holding.
UBS AM first reported a position in Cartesian Therapeutics in Q4 2025 and has held it in 3 quarters since.
95 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.